Early initiation of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin did not result in a statistically significant improvement in diuretic efficiency relative to structured usual ...
MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRX) (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions ...
Madrid, Spain – 30 August 2025: In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted ...
Rates of inpatient dialysis initiation are higher for patients with chronic kidney disease and heart failure than those without heart failure. HealthDay News — Patients with chronic kidney disease ...
Findings showed that patients treated with empagliflozin were 36% more likely to experience a clinical benefit. Treatment with empagliflozin was shown to improve clinical outcomes in adults ...
Evidence continues to support initiation of sodium glucose cotransporter 2 inhibitors in patients with heart failure. The initial decline in estimated glomerular filtration rate (eGFR) after starting ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology ...
More frequent placement of central venous catheter seen for patients with heart failure with reduced ejection fraction. (HealthDay News) — Patients with chronic kidney disease (CKD) and heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results